GIP and Insulin resistance: Additionally, bioactive peptides activate the release of incretin hormones (gastric inhibitory polypeptide and GLP-1), which improve insulin resistance and inhibit dipeptidyl peptidase-IV, consequently reducing the degradation of gastric inhibitory polypeptide and GLP-1 [37].